Chlamydia trachomatis infections of the female genital tract: State of the art

Annals of Medicine

Volumn 44, Issue 1, 2012, Pages 18-28

  Paavonen, Jorma ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chlamydia trachomatis; female genital tract; sexually transmitted infections

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; OFLOXACIN;

CANCER RISK; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL FEATURE; FEMALE GENITAL TRACT INFECTION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SCREENING; SINGLE DRUG DOSE; UTERINE CERVIX CANCER; WART VIRUS;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84856255743     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.546365     Document Type: Review

References (91)

1. Land JA, Van Bergen JEAM, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update. 2010:16:189-204.
2. Kalwij S, Macintosh M, Baraitser P. Screening and treat ment of Chlamydia trachomatis infections. BMJ. 2010;340:912-7.
3. ECDC Guidance: Chlamydia control in Europe, 2009. Available at: www.ecdc.europa.eu. (Accessed date: 29 December 2010).
4. Morre SA, Rozendaal L, Van Valkengoed IG, Boeke AJ, Van Voorst Vader PC, Schirm J, et al. Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J Clin Microbiol. 2000;38:2292-6. (Pubitemid 30414353)
5. Wilson JS, Honey E, Templeton A, Paavonen J, Mårdh PA, Stary A, et al.; EU Biomed Concerted Action Group. A systematic review of the prevalence of Chlamydia trachomatis among European women. Hum Reprod Update. 2002;28: 385-94. (Pubitemid 34919252)
6. van Bergen J, Spaargaren J, Göt z HM, Veldhuijzen IK, Bindels PJE, Coenen TJ, et al.; the PILOT CT study-group. Population prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in the Netherlands. BMC Infect Dis. 2006;6:42.
7. van Bergen J, Gotz HM, Richardus JH, Hoebe CJ, Broer J, Coenen AJ. Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. Sex Transm Infect. 2005;81:17-23. (Pubitemid 40222861)
8. Andersen B, Olesen F, Moller JK, Ostergaard L. Population-based strategies for outreach screening of urogenital Chlamydia trachomatis infections: a randomized, controlled trial. J Infect Dis. 2002;185:252-8. (Pubitemid 34056450)
9. Macleod J, Salisbury C, Low N, McCarthy A, Sterne JA, Holloway A, et al. Coverage and uptake of systematic postal screening for Chlamydia trachomatis and prevalence of infection in the United Kingdom general population: cross sectional study. BMJ. 2005;330:940-2. (Pubitemid 40592313)
10. Low N; the SCREen project team. Publication report on chlamydia control activities in Europe. Euro Surveill. 2008; 13: pii: 18924.
11. Tu W, Batteiger B, Wiehe S, Ofner S, Van Der Pol B, Katz BP, et al. Time from first intercourse to first sexually transmitted infection diagnosis among adolescent women. Arch Pediatr Adolesc Med. 2009;163:1106-11.
12. Centers for Disease Control and Prevention (CDC). Chlamydia screening among sexually active young female enrollees of health plans-United States, 2000-2007. MMWR Morb Mortal Wkly Rep. 2009;58:362-5.
13. Aral SO, Fenton KA, Holmes KK. Sexually transmitted disease in the USA. Temporal trends. Sex Transm Infect. 2007;83:257-66. (Pubitemid 47242501)
14. Paavonen J; FUTURE II Study Group. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16718) vaccine trials. Curr Med Res Opin. 2008;24:1-12.
15. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA). Final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-14.
16. Egger M, Low N, Smith GD, Lindblom B, Hermann B. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. BMJ. 1998;316:1776-80. (Pubitemid 28269151)
17. Simms I, Talebi A, Rhia J, Horner P, French RS, Sarah R, et al. The English National Screening Programme: variation in positivity in 2007/2008. Sex Transm Dis. 2009;36: 522-7.
18. Franklin N, O'Connor CC, Shaw M, Guy R, Grulich A, Fairley CK, et al. Chlamydia at an inner metropolitan sexual health clinic Sydney, NSW; the Australain collaboration for chlamydia enhanced sentinal surveillance (ACCESS) Project. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Hof bei Salzburg, Austria, 20-25 June 2010. p. 413.
19. Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard D, Orr DP, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010;201:42-51.
20. Lyytikäi nen E, Kaasila M, Koskela P, Lehtinen M, Patama T, Pukkala E, et al. Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. Sex Transm Infect. 2008; 84: 19-22. (Pubitemid 351195845)
21. Kretzshmar M, Turner KME, Barton PM, Edmunds WJ, Low N. Predicting the population impact of chlamydia screening programmes: comparative mathematical modelling study. Sex Transm Infect. 2009;85:359-66.
22. Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachoamatis in women 15 to 29 years of age: a costeffectiveness analysis. Ann intern Med. 2004;141:501-14.
23. Adams EJ, Tirner KME, Edmonds WJ. The cost effective ness of opportunistic Chlamydia screening in England. Sex Transm Inf. 2007;83:267-75.
24. De Vries R, Van Bergen JEAM, De Jong-van den Berg LTW, Postma PJ; the PILOT-CT study Group. Cost-utility of repeated screening for Chlamydia trachomatis. Value Health. 2008;11:272-4. (Pubitemid 351473602)
25. Paavonen J. Memorable Chlamydia trachomatis papers. Sex Transm Infect. 2000;76:S30-2.
26. Wiesenfeld H, Paavonen J. Pelvic inflammatory disease In: Morse SA, Ballard RC, Holmes KK, Moreland A, editors. Atlas of sexually transmitted disease and AIDS. 4th ed. London, UK: Elsevier Ltd. 2010, p. 94-110. In press.
27. van Valkengoed I, MorréS, van den Brule A, Meijer CJ, Bouter LM, Boeke AJ. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes-implications for cost-effectiveness analyses. Int J Epidemiol. 2004;33:416-25. (Pubitemid 38578847)
28. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, Lindblom B, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women' s Cohort Study. Sex Transm Infect. 2006;82:212-8. (Pubitemid 43901588)
29. Bakken IJ, Ghaderi S. Incidence of pelvic inflammatory disease in a large cohort of women tested for Chlamydia trachomatis: a historical follow-up study. BMC Infect Dis. 2009;9:130-4.
30. Bjartling C, Osser S, Persson K. Chlamydia trachomatis is still in common in pelvic inflammatory disease in the south of Sweden. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Hof bei Salzburg, Austria, 20-25 June 2010. p. 389.
31. Mårdh P-A, Ripa T, Svensson L, Weström L. Chlamydia trachomatis infection in patients with acute salpingitis. N Engl J Med. 1977;296:1377-9. (Pubitemid 8127339)
32. Öhman H, Tiitinen A, Halttunen M, Lehtinen M, Paavonen J, Surcel HM. Cytokine polymorphisms and severity of tubal damage in women with chlamydia-associated infertility. J Infect Dis. 2009;199:1353-9.
33. Öhman H, Tiitinen A, Halttunen M, Birgelund S, Christiansen G, Koskela P, et al. IL-10 polymorphism and cell mediated immune response to chlamydia trachomatis. Genes Immun. 2006;7:243-9.
34. Wang W, Stassen FR, Surcel H-M,Öhman H, Tiitinen A, Paavonen J, et al. Analyses of polymorphism in inflammasome-associated NLRP3 and miRNA-146A genes in the susceptibility to and tubal pathology of Chlamydia trachomatis infection. Drugs Today (Barc). 2009;45, Suppl B: 95-103.
35. Öhman H, Bailey R, Natividad A, Tiitinen A, Halttunen M, Paavonen J, et al. Il-12p40 polymorphisms and C. trachomatis specific lymphocyte proliferative responses. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Salzburg, Austria, 20-25 June 2010. Abstract. p. 169-72.
36. Schachter J, Hill EC, King EB, Coleman VR, Jones P, Meyer KF. Chlamydia infection in women with cervical dysplasia. Am J Obstet Gynecol. 1975;123:753-7.
37. Paavonen J, Vesterinen E, Meyer B, Saikku P, Suni J, Purola E, et al. Genital Chlamydia trachomatis infections in patients with cervical atypia. Obstet Gynecol. 1979;54:289-91. (Pubitemid 9218487)
38. Koskela P, Anttila T, Björge T, Brunsvig A, Dillner J, Hakama M, et al. Chlamydia trachomatis infection and invasive cervical cancer. Int J Cancer. 2000;85:35-9.
39. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikäheimo I, et al. Serotypes of Chlamydia trachomatis and risk for cervical squamous cell carcinoma. JAMA. 2001;285: 47-51. (Pubitemid 32042715)
40. Paavonen J, Karunakaran KP, Noguchi Y, Anttila T, Bloigu A, Dillner J, et al. Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol. 2003; 189:1287-92. (Pubitemid 37542159)
41. Johanson KA, Chen AL, Tan M, Sütterlin C. The role of the protease CPAF in chlamydia-induced centronome amplifi-cation. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, Hof bei Salzburg, Austria, 20-25 June 2010. Oral presentation.
42. Schiffman M, Castle PE, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. (Pubitemid 47371147)
43. Lehtinen M, Lyytikäi nen E, Koskela P, Surcel H-M, Paavonen J. Chlamydia trachomatis and risk for cervical neoplasia-a meta-analysis of longitudinal studies. Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Salzburg, Austria, 20-25 June 2010. Abstract. p. 445-8.
44. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prevent. 1995;4:447-51.
45. Ness RB, Shen C, Bass, Jackson C, Moysich K, Edwards R, et al. Chlamydia trachomatis serology in women with and without ovarian cancer. Infect Dis Obstet Gynecol. 2008; 16:1-5.
46. Idahl A, Lundin E, Elgh F, Jurstrand M, Møller JK, Marklund I, et al. Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol. 2010;202:71.e1-6.
47. Riska A, Finne P, Alfthan H, Anttila T, Jalkanen J, Sorvari T, et al. Past chlamydial infection is not associated with primary fallopian tube carcinoma. Eur J Cancer. 2006;42:1835-8. (Pubitemid 44149083)
48. Morin-Papunen L, Duleba A, Bloigu A, Jär velin MR, Saikku P, Pouta A. Chlamydia antibodies and self-reported symptoms of oligo-amenorrhea and hirsutism: a new etiologic factor in polycystic ovary syndrome. Fertil Steril. 2010;94: 1799-804.
49. Tikkanen M, Surcel H-M, Boigu A, Nuutila M, Hiilesmaa V, Ylikorkala O, et al. Prediction of placental abruption by testing for C-reactive protein and chlamydial antoibody levels in early pregnancy. BJOG. 2008;115:486-91. (Pubitemid 351225162)
50. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis infection-impact on human reproduction. Hum Reprod Update. 1999;5:433-47. (Pubitemid 29512131)
51. Joki-Korpela P, Sahrakorpi N, Halttunen M, Surcel HM, Paavonen J, Tiitinen A. The role of Chlamydia trachomatis in male infertity. Fertil Steril. 2009;91:S1448-50.
52. Tiitinen A, Surcel H-M, Halttunen M, Birkelund S, Bloigu A, Christiansen G, et al. Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cellmediated responses predict tubal factor infertility. Hum Reprod. 2006;21:1533-8. (Pubitemid 44445033)
53. Jespersen DJ, Flatten KS, Jones MF, Smith TF. Prospective comparison of cell culture and nucleic acid amplification tests for laboratory diagnosis of Chlamydia trachomatis infections. J Clin Microbiol. 2005;43:5324-6. (Pubitemid 41484051)
54. Chernesky M, Jang D, Smieja M, Portillo E, Ewert R, Pritchard C, et al. Validation of the APTIMA Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath liquid-based pap test samples taken with different collection devices. Sex Transm Dis. 2009;36:581-3.
55. Masek BJ, Arora N, Quinn N, et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of selfcollected vaginal swabs obtained via an internet-based screening program. J Clin Microbiol. 2009;47:1663-7.
56. Quint K, Porras C, Safaeian M, González P, Hildesheim A, Quint W, et al. Evaluation of a novel PCR-based assay for detection and identification of Chlamydia trachomatis serovars in cervical specimens. J Clin Microbiol. 2007;45:3986-91. (Pubitemid 350274881)
57. Quint K, van Doorn L-J, Kleter B, de Koning MN, van den Munckhof HA, Morre SA et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J Mol Diagn. 2007;9:631-8. (Pubitemid 350158423)
58. Mahilum-Tapay L, Laitila V, Wawrzyniak JJ, Lee HH, Alexander S, Ison C, et al. New point of care Chlamydia Rapid Test-bridging the gap between diagnosis and treatment: performance evaluation study. BMJ. 2007;335: 1190-4. (Pubitemid 350273302)
59. MorréSA, Catsburg A, de Boer M, Spaargaren J, de Vries HJ, Schirm J, et al. Monitoring the potential introduction of the Swedish Chlamydia trachomatis variant (swCT) in the Netherlands. Euro Surveill. 2007;12:318-20.
60. de Barbeyrac B, Raherison S, Cado S, Normandin F, Clerc M, Clairet V, et al. French situation concerning the Swedish Chlamydia trachomatis variant. Euro Surveill. 2007;12:321-2.
61. Reischl U, Straube E, Unemo M. The Swedish new variant of Chlamydia trachomatis (nvCT) remains undetected by many European laboratories as revealed in the recent PCR/NAT ring trial organised by INSTAND e.V., Germany. Euro Surveill. 2009; 14; pii: 19302.
62. Lagergår d T, Hadad R, Tunbäck P, Lindholm L, Löw hagen GB, Unemo M. Distribution of Chlamydia trachomatis ompA genovars and the new variant of C. trachomatis in the Göteborg area, Sweden. Eur J Clin Microbiol Infect Dis. 2010;29:609-11.
63. Bjartling C, Osser S, Johnsson A, Persson K. Clinical manifestation and epidemiology of the new genetic variant of chlamydia trachomatis. Sex Transm Dis. 2009;36:529-35.
64. Christerson L, Klint M, Hadad R, LoréB, Anagrius C,österlund A, et al. The proportion of the new variant of Chlamydia trachomatis is converging in Sweden counties over time. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Hof bei Salzburg, Austria, 20-25 June 2010. p. 401.
65. Clarke IN, Hammas B, Beerens AMJ, Luijt DS, Westh H, Nilsson P, et al. Detection and spread of new variant Chlamydia trachomatis in northern European countries. In: Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, International Chlamydia Symposium, Hof bei Salzburg, Austria, 20-25 June 2010. p. 397.
66. Johnson AM, Horner P. A new role for Chlamydia trachomatis serology. Sex Transm Infect. 2008;84:79-80. (Pubitemid 351497911)
67. Traharne JD, Ripa KT, Mårdh PA, Svensson L, Weström L, Darougar S. Antibodies to Chlamydia trachomatis in acute salpingitis. Br J Vener Dis. 1979;55.26-9.
68. Akande VA, Hunt LP, Cahill DJ, Caul EO, Ford WCL, Jenkins JM. Tubal damage in infertile women: prediction using chlamydia serology. Hum Reprod. 2003;18:1841-7. (Pubitemid 37107556)
69. Gijsen AP, Land JA, Goossens VJ, Slobbe MEP, Bruggeman CA. Chlamydia antibody testing in screening for tubal factor subfertility: the significance of IgG antibody decline over time. Hum Reprod. 2002;17:699-703. (Pubitemid 34232440)
70. Piura B, Sarov B, Sarov I. Persistance of antichlamydial antibodies after treatment of acute salpingitis with doxycycline. Eur J Obstet Gynecol Reprod Biol. 1993;48:117-21. (Pubitemid 23108942)
71. Henry-Suchet J, Askienay-Elbhar M, Thibon M, Revol C, Akue BA. The post-therapeutic course of serum antibody titres in women with acute salpingitis and tubal infertility. Fertil Steril. 1994;62:296-304. (Pubitemid 24233279)
72. Tobin JM, Harinda V, Mani R. Which treatment for genital tract Chlamydia trachomatis infection? Int J STD AIDS. 2004;15:737-9. (Pubitemid 39540699)
73. Lamontagne S, Baster K, Emmett L, Nichols T, Randell S, McLean L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. Sex Transm Infect. 2007;83:292-303. (Pubitemid 47242508)
74. Centers for Disease Control and Prevention. Chlam ydia screening fact sheet. Available at: www.cdc.gov/std/Chlamydia/STDFact-Chlamydia.htm.
75. Igietseme JU, He Q, Joseph K, Eko FO, Lyn D, Ananaba G, et al. Role of T lymphocytes in the pathogenesis of chlamydia disease. J Infect Dis. 2009;200:926-34.
76. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature. 2005;5:149-61. (Pubitemid 40208904)
77. European Centre for Disease Prevention and Control. Chlamydia control in Europe. Available at: 2009.wwwecdc. europa.eu/en/publications/Publications(0906- GUI-Chlamydia-Control-in-Europe.pdf.
78. Gaydos CA, Wright C, Wood B, Waterfield G, Hobson S, Quinn TC. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis. 2008;35:233-7. (Pubitemid 351619517)
79. Fung M, Scott K, Kent C, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect. 2007;83:304-9. (Pubitemid 47242509)
80. Brunham R, Rekart M. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis. 2008;35:53-4. (Pubitemid 351619350)
81. Lyytikäi nen E, Kaasila M, Hiltunen-Back E, Lehtinen M, Tasanen K, Surcel HM, et al. A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003. BMC Infect Dis. 2008;8:169-74.
82. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352:676-85. (Pubitemid 40239215)
83. C ameron ST, Glasier A, Scott G, Young H, Melvin L, Johnstone A, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod. 2009;24:888-95.
84. Owens SL, Arora N, Quinn N, Peeling RW, Holmes KK, Gaydos CA. Utilising the internet to test for sexually transmitted infections: results of a survey and accuracy testing. Sex Transm Infect. 2010;86:112-6.
85. Arnheim L. Immunological responses in genital HPV infections and etiology of cervical cancer. Thesis. Stockholm: Karolinska Institute; 2005.
86. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ. 1996;312:537-9. (Pubitemid 26070265)
87. Naucler P, Chen H-C, Persson K, You SL, Hsieh CY, Sun CA, et al. Seroprevalence of human papillomavirus and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol. 2007;88:814-22. (Pubitemid 46359550)
88. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-8.
89. Lehtinen M, Ault K, Lyytikäinen E, Dillner J, Garland SM, Ferris DG, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. In press.
90. Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, et al. Association of Chlamydia trachomatis with persistence of high-risk of human papillomavirus in a cohort of female adolescents. Am J Epidemiol. 2005;162:668-75. (Pubitemid 41437366)
91. Silins I, Ryd W, Strand A, Törnberg S, Hansson BG, Wang X, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer. 2005;116:110-5. (Pubitemid 40827763)